CTOs on the Move

Future Family

www.futurefamily.com

 
Future Family is where women, men and couples start their fertility journey. The company`s mission is to make fertility care accessible and affordable to all.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Future Family raised $10M on 10/18/2018
Future Family raised $100M on 12/12/2018

Similar Companies

CENTOGENE

CENTOGENE - transforming genetic data into medical decisions. We are one of the worldwide leaders in the field of early genetic diagnostics for rare hereditary diseases. A data repository of genetic data from over 115 countries gives us a unique access to epidemiological, clinical and genetic information on hereditary disorders, including oncogenetic indications. We focus exclusively on providing the highest quality, patient-centred service, verified by multiple international accreditations (ISO, CAP, CLIA), regular pharmaceutical audits and our outstanding short turn-around times for analysis. We believe our medical expertise is based on cutting-edge technologies including whole exome/genome sequencing, innovative biomarkers and continued R&D. Our mutation database (CentoMD®) is the worlds largest for rare genetic diseases and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation. CENTOGENE is a key partner for many high-profile pharmaceutical companies who are active in the orphan drug development.

Southwest FLA Regional Imaging

Southwest FLA Regional Imaging is a Punta Gorda, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Noramco

Noramco, Inc. is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

RAPT Therapeutics

RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the company develops highly selective small molecules that are designed to modulate the fundamental immune responses underlying these diseases. RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4, including our lead oncology drug candidate, FLX475, now in clinical development and our lead inflammation drug candidate, RPT193, expected to enter the clinic in the second half of 2019. The company is also pursuing other discovery targets including GCN2 and HPK1 for the treatment of cancer.

Drug Development Resources

Drug Development Resources is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.